Pharmaceuticalses Rexahn Enters Test Phase II For ZoraxelTM to Address Dysfunction Erectile

Rexahn Pharmaceuticals, Inc., biopharmaceutical COMPANY was denoted in opening, development, and commercialization of the progressive processing for cancerous, central nervious system disturbances, Online viagra sexual dysfunction and other unjustified medical need, declared that Company entered clinical test the Phase II for its leaden clinical composition ZoraxelTM, for processing the Dysfunctions Erectile (RED.). ZoraxelTM is DEVELOPED as verbally control, on-requirement-use the tablet.

Zoraxel Test Phase II - double-blind, operated analysis This is much-test the centre is expected by the end of 2008 to be complete.

Commenting on present-day news, Dr. Chang H. Ahn, Chairman and GENERAL MANAGER Rexahn, noted, “We very pleased to declare the initiation of the other test Phase II. ZoraxelTM will PROVE itself more efficient, more toxic therapy for patient with erectile dysfunction.”

About ZoraxelTM

ZoraxelTM is DEVELOPED as immediate tablet of the issue and has well-installed and excellent safe profile different from the current market, leading inhibitors PDE-5 with much side effects (priapism, serious hypotension, myocardial infarction, sudden mortal, raised intraocular pressure and sudden listening the loss). Zoraxel - double neurotransmitter stretcher in brain, and thereby, actions through central nervious system, which adjusts the sexual functions since inhibitors PDE-5 work at peripheral blood ship and influence upon only erectile function. In model study, ZoraxelTM is shown to vastly perfect all three functions to sexual activity that is to say sexual awakening, building, and issue. As such, ZoraxelTM can be an more efficient processing ED. for patient, which - as supportive so and unresponsive in inhibitors PDE-5.

About Dysfunctions Erectile (RED.)

ED. is determined as consequent impossibility to reach and support the building sufficient for satisfactory sexual intercourse. It Is Evaluated to affect up to 30 million mans in United Staff, with 52% mans between age 40 and 70 reporting difficulties with erectile function. To year 2025, is evaluated that 322 million mans worldwide damages from a certain degree of the sexual dysfunction. Clinical management ED. developed to a considerable extent for the last years. Advancement phosphodiesterase-5 inhibitors (PDE-5) therapy quickly accompanied scientific understanding nitric oxide (NO) signalizing mechanism on erectile fabrics. The Disadvantage events, influencing upon system were a main enxiety medicine, which adjusts this answer. The Studies in neurotransmission involved in penile building, actions of the Online Generic Viagra hormone were included in this answer, and biochemical signal transduction is processed within fabrics erectile, is indicative of significant area scientific searching for.

About Rexahn Pharmaceuticals, Inc.

The Pharmaceuticalses Rexahn is biopharmaceutical company, used as lever personal platform to technologies to find, develop and commercialize progressive processing for cancerous, central nervious system disturbances, sexual dysfunction and other unjustified medical need. The Compositions Rexahn’s are intended uniquely to address the different conditions a disease under vastly reduction side effect to allow to restore their quality to lifes. For Additional information on visit Rexahn

This press release contains statement (including forecasts and business directions) that - forward to look statement. The Actual results Rexahn’s can differ vastly from expected result and waiting were expressed in this forward to look statement as a result determined risk and uncertainties, including, defect Rexahn’s incom, qualifications enxiety auditor to go and need for additional capital to service its deal (the business) to develop their own candidate of the product; the risk that measures of the development Rexahn’s refer to its candidate of the product can not be a success; the possibility is unable to get the plenipotentiary approval a candidate product Rexahn’s; the risk that results of the clinical test can be not terminated in time or support claim Rexahn’s; the demand for and market acceptance candidate medicine Rexahn’s; The Confidence Rexahn’s on researcher third party and manufacturers to develop their own candidate of the product; The Ability Rexahn’s to develop and get protection its intellectual characteristic; and the other risk postpones stated now and then in our sawdust with Commission of the Securities And exchange. This is forward to look statement is made according to date in respect of this; Rexahn does Not Take no obligation to correct this forward to look statement.